Abstract:Background: Waning of neutralizing titers and decline of protection shorter after the second dose of COVID-19 vaccines was observed, including China-made inactivated vaccines. Efficacy of a heterologous boosting using one dose recombinant SARS-CoV-2 fusion protein vaccine (V-01) in inactivated vaccine-primed population was studied, aimed to restore the immunity.Methods: A randomized, double-blind and placebo-controlled phase Ⅲ trial was conducted in healthy people aged 18 years or older in Pakistan and Malaysia. Each eligible participant received one dose of V-01 vaccine developed by Livzon Mabpharm Inc . or placebo 3-6 months after the 2-dose primary regimen, and was monitored for safety and efficacy. The primary endpoint was protection against confirmed symptomatic SARS-CoV-2 infection.Results: A total of 10,218 participants were randomly assigned to receive vaccine or placebo. Virus-neutralizing antibodies were assessed in 419 participants. A dramatical increase (11.3-fold; 128.3 to 1452.8) of neutralizing titers was measured in V-01 group at 14 days after the booster. Over the two months surveillance, vaccine efficacy was 47.8% (95%CI: 22.6 to 64.7) according to the intention-to-treat principle. The most common adverse events were transient, mild-to-moderate pain at the injection site, fever, headache, and fatigue. Serious adverse events occurred almost equally in V-01 (0.12%) and placebo (0.16%) groups. Conclusion: The heterologous boosting with V-01 vaccine was safe, efficacious, and could elicit robust humoral immunity under the epidemic of the Omicron variant.Trial Registration Details: The study was registered with ClinicalTrials.gov (number: NCT05096832).Funding Information: Funded by Livzon Mabpharm Inc. Declaration of Interests: FJ, WD, and XY are employees of the Joincare Pharmaceutical Group Industry Co., Ltd.; ZHX, JMY, and YZ are employees of the Livzon Mabpharm Inc., Joincare holds Livzon. All other authors declare no competing interests.Ethics Approval Statement: The protocol was approved by the ethics review committees of each study sites, and written informed consent was obtained from each participant before enrollment.

An updated RBD-Fc fusion vaccine booster increases neutralization of SARS-CoV-2 Omicron variants

Homologous or Heterologous Booster of Inactivated Vaccine Reduces SARS-CoV-2 Omicron Variant Escape from Neutralizing Antibodies

Efficacy of Heterologous Boosting Using Recombinant SARS-CoV-2 Fusion Protein Vaccine: A Randomized, Double-Blind and Placebo-Controlled Phase III Trial

Extensive neutralization against SARS-CoV-2 variants elicited by Omicron-specific subunit vaccine as a heterologous booster

An Omicron-Based Vaccine Booster Elicits Potent Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants in Adults.

Enhanced neutralization of SARS-CoV-2 XBB sub-lineages and BA.2.86 by a tetravalent COVID-19 vaccine booster

Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant

Enhanced Neutralization of SARS-CoV-2 by a Tetravalent COVID-19 Vaccine Booster

Bivalent mRNA vaccine improves antibody-mediated neutralization of many SARS-CoV-2 Omicron lineage variants

Enhanced neutralization of SARS-CoV-2 variant BA.2.86 and XBB sub-lineages by a tetravalent COVID-19 vaccine booster

XBB.1.5 monovalent booster improves antibody binding and neutralization against emerging SARS-CoV-2 Omicron variants

mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines

A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS‐CoV‐2 variants including BA.1 and BA.2 in vaccinated mice

RBD-mRNA Vaccine Induces Broadly Neutralizing Antibodies Against Omicron and Multiple Other Variants and Protects Mice from SARS-CoV-2 Challenge.

Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants

The impact of CoronaVac on the neutralization breadth and magnitude of the antibody response to SARS-CoV-2 viruses

Extended SARS-CoV-2 RBD booster vaccination induces humoral and cellular immune tolerance in mice

Efficacy of the neutralizing antibodies after the booster dose on SARS-CoV-2 Omicron variant and a two-year longitudinal antibody study on Wild Type convalescents

RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response

Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination

Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice